Wang Qiang, Hu Shi-Cheng, Yang Chun-Sheng, Chen Jia-Cun, Zheng Jun-Nian, Sun Xiao-Qing, Wang Jun-Qi
The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210046, P.R. China.
Department of Urology, The Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China.
Oncol Lett. 2017 Dec;14(6):6592-6596. doi: 10.3892/ol.2017.7006. Epub 2017 Sep 20.
Despite previous advances, the treatment options for prostate cancer remain limited. For the purposes of gene knockdown, the utility of RNA interference has been demonstrated and is considered to have therapeutic potential. In the present study, a short hairpin RNA (shRNA) was used to assess the effect of special AT-rich sequence binding protein (SATB1) downregulation on the growth and metastatic potential of prostate cancer in xenograft nude mice. A plasmid carrying shRNA targeting SATB1, pSilencer-SATB1-shRNA, was successfully engineered. Using this plasmid, significant downregulation of SATB1 mRNA and protein expression in the DU145 prostate cancer cells was observed. pSilencer-SATB1-shRNA was demonstrated to be markedly efficacious against prostate cancer xenografts in nude mice. These results may lead to a novel method of improving gene therapy efficacy against prostate cancer via regulating the function of SATB1.
尽管此前已取得进展,但前列腺癌的治疗选择仍然有限。就基因敲低而言,RNA干扰的效用已得到证实,并被认为具有治疗潜力。在本研究中,使用短发夹RNA(shRNA)来评估富含AT序列结合蛋白(SATB1)下调对异种移植裸鼠前列腺癌生长和转移潜能的影响。成功构建了携带靶向SATB1的shRNA的质粒pSilencer-SATB1-shRNA。使用该质粒,观察到DU145前列腺癌细胞中SATB1 mRNA和蛋白表达显著下调。pSilencer-SATB1-shRNA被证明对裸鼠前列腺癌异种移植具有显著疗效。这些结果可能会带来一种通过调节SATB1功能来提高前列腺癌基因治疗疗效的新方法。